Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.85 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 4/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 4/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94902 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL1776088 | 0.90 | GDA (0.96) | GDAPAX8LMNATSHRALDH1A1 | |
| SCHEMBL101340 | 0.75 | — | — | |
| SCHEMBL2202786 | 0.73 | GDA (0.60) | GDAALDH1A1KDM4ESMN1; SMN2GAA | |
| Phosphoric Acid SCHEMBL7627085 | 0.73 | GDA (0.46) | GDAPAX8LMNATSHRALDH1A1 | |
| SCHEMBL21286900 | 0.73 | GDA (0.60) | GDAPAX8LMNATSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL6016843 | 0.72 | GDA (0.56) | GDAPAX8LMNATSHRALDH1A1 | |
| SCHEMBL13219030 | 0.71 | — | — | |
| SCHEMBL343999 | 0.71 | GDA (0.63) | GDAPAX8LMNATSHRALDH1A1 | |
| Ribose (Furanose) SCHEMBL218015 | 0.71 | GDA (0.59) | GDALMNATSHRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120156138-A1 | Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming | SMITH LARRY J (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2010120262-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MEDICAL CONDITIONS INVOLVING CELLULAR PROGRAMMING | SMITH HOLDINGS, LLC (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100172966-A1 | Methods and compositions for cellular reprogramming | FUJI ELECTRIC CO., LTD. (JP) | 2010-07-08 | — | — | US | disclosed |
| US-20100010065-A1 | Methods and Compositions for Cellular Reprogramming | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2010-01-14 | — | — | US | disclosed |
| US-7517644-B1 | Administering an expression vector, a double stranded oligodeoxynucleotide, or an antisense oligodeoxynucleotide to treat cancer, AIDS or other Aberrant Programming Disease; regulating expression of a transcriptional regulator; antiapoptosis | Smith, Larry J. (US) | 2009-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156138-A1 | Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming | CKMT1A; CKMT1B, ATF4, NFATC1 | GDA 293/4885PAX8 409/4885LMNA 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.